长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效观察

A Clinical Observation of Vinorelbine Combined with Cisplatin in the Treatment of Advanced Stage Non-small-cell Lung Cancer

目的：观察长春瑞滨联合顺铂（NP方案）治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副作用。方法：42例经病理或细胞学诊断为非小细胞肺癌患者，其中腺癌4例，鳞癌38例。TNM分期Ⅲ期23例，Ⅳ期19例。所有病例均为初治。采用国产长春瑞滨25mg／m^2，第1、8天静滴；顺铂（DDP）30mg／m^2第1～3天静滴，28d为一个周期。治疗至少2个周期后进行疗效和毒性反应评价。结果：完全缓解（CR）3例，部分缓解（PR）15例，稳定（SD）16例，进展（PD）8例，总有效率（CR＋PR）为42．9％。主要毒副反应为白细胞减少及胃肠道反应，其Ⅲ、Ⅳ度白细胞下降占11．9％，呕吐发生率为54．7％。结论：长春瑞滨联合顺铂（NP方案）治疗晚期NSCLC疗效确切，毒副反应可耐受。

Objective： To observe the efficacy and toxicity of vinorelbine combined with cisplatin （NP regimen） in the treatment of advanced non-small-cell lung cancer（NSCLC）. Methods：42 patients with advanced NSCLC were confirmed by pathology or cytology. There were 4 patients with lung adenocarcinoma,38 with squamous carcinoma. 23 patients had stage Ⅲ diease and 19 patients had stage Ⅳ. All patients had no prior chemotherapy. NVB were used 25 mg per centiare on days 1 and days 8;DDP were used 30 mg per centiare on days 1 to days 3. A Period includes 28 days. to evaluate the efficacy and toxicity after 2 periods at least. Results：Complete response was observed in 3 patients and partial response was observed in 15 patients. The overall response rate was 42.9%. The main tocicity was leucopenia and vomiting. The dose limiting toxicity was neutropenia that was observed in 83.3% of the patients（11.9% in grades Ⅲ and Ⅳ）. About 54.7% of the patients was observed vomitting. Conclusions： The results indicate NP regimen for advanced NSCLC is promise,and the toxicities are tolerable.